Andrew Rawstron
Overview
Explore the profile of Andrew Rawstron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munir T, Cairns D, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al.
N Engl J Med
. 2023 Dec;
390(4):326-337.
PMID: 38078508
Background: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment...
2.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al.
Lancet Oncol
. 2023 May;
24(5):535-552.
PMID: 37142374
Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients...
3.
Allsup D, Craig Z, Cairns D, Howard D, Hockaday A, Bloor A, et al.
Am J Hematol
. 2022 Feb;
97(5):E168-E171.
PMID: 35108412
No abstract available.
4.
Wierda W, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown J, et al.
Leukemia
. 2021 Jun;
35(11):3059-3072.
PMID: 34168283
Assessment of measurable residual disease (often referred to as "minimal residual disease") has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and...
5.
Pepper A, Zucchetto A, Norris K, Tissino E, Polesel J, Soe Z, et al.
Leukemia
. 2021 Jun;
36(1):271-274.
PMID: 34148055
No abstract available.
6.
Lamb M, Smith A, Painter D, Kane E, Bagguley T, Newton R, et al.
BMJ Open
. 2021 Feb;
11(2):e041296.
PMID: 33619185
Objective: To examine mortality and morbidity patterns before and after premalignancy diagnosis in individuals with monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL) and compare their secondary...
7.
Appleby N, Eyre T, Cabes M, Jackson A, Boucher R, Yates F, et al.
BMC Cancer
. 2019 May;
19(1):471.
PMID: 31109313
Background: Transformation of chronic lymphocytic leukaemia (CLL) to diffuse large B-cell lymphoma (DLCBL) type Richter's syndrome (RS) carries a dismal prognosis. Standard-of-care chemoimmunotherapy for de novo RS is inadequate with...
8.
Norris K, Hillmen P, Rawstron A, Hills R, Baird D, Fegan C, et al.
Leukemia
. 2019 Feb;
33(8):1953-1963.
PMID: 30700843
We have previously shown that dividing patients with CLL into those with telomeres inside the fusogenic range (TL-IFR) and outside the fusogenic range (TL-OFR) is powerful prognostic tool. Here, we...
9.
Richardson S, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, et al.
Br J Haematol
. 2013 Jan;
160(5):640-8.
PMID: 23293871
Following reduced intensity-conditioned allogeneic stem cell transplantation (RIC allo-SCT) for chronic lymphocytic leukaemia (CLL), there is an inverse relationship between relapse and extensive chronic graft-versus-host disease (GVHD). We evaluated outcomes...
10.
Pettitt A, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al.
J Clin Oncol
. 2012 Apr;
30(14):1647-55.
PMID: 22493413
Purpose: In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In contrast, TP53 defects are not associated with resistance to...